Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Jun;23(3):224-7.
doi: 10.1097/MEJ.0000000000000292.

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks

Hilary J Longhurst  1 , Werner Aberer, Laurence Bouillet, Teresa Caballero, Marcus Maurer, Vincent Fabien, Andrea Zanichelli; IOS Study Group
Affiliations
Observational Study

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks

Hilary J Longhurst et al. Eur J Emerg Med. 2016 Jun.

Abstract

Objective: To characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry.

Methods: This retrospective analysis was based on data from patients with HAE type I/II who received healthcare professional-administered or self-administered icatibant to treat laryngeal attacks between September 2008 and May 2013.

Results: Twenty centers in seven countries contributed data. Overall, 42 patients with HAE experienced 67 icatibant-treated laryngeal attacks. Icatibant was self-administered for 62.3% of attacks (healthcare professional-administered, 37.7%). One icatibant injection was used for 87.9% of attacks, with rescue or concomitant medication used for 9.0%. The median time to treatment was 2.0 h (n=31 attacks) and the median time to resolution was 6.0 h (n=35 attacks).

Conclusions: This analysis describes successful use of icatibant for the treatment of laryngeal HAE attacks in a real-world setting.

PubMed Disclaimer

References

    1. Bernstein JA, Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med 2012; 5:39. - PMC - PubMed
    1. Craig T, Aygören-Pürsün E, Bork K, Bowen T, Boysen H, Farkas H, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5:182–199. - PMC - PubMed
    1. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130:692–697. - PubMed
    1. European Medicines Agency. Firazyr summary of product characteristics. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici.... [Accessed 2 April 2014].
    1. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532–541. - PMC - PubMed

Publication types

MeSH terms

Associated data